SNDX
NASDAQSyndax Pharmaceuticals Inc.
News · 26 weeks38+50%
2026-04-192026-10-11
Mix1190d
- Other7(64%)
- Earnings2(18%)
- SEC Filings2(18%)
Latest news
25 items- PRSyndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 ListNEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj® (revumenib), the Company’s first-in-class menin inhibitor, has been selected by TIME as one of the "Best Inventions of 2026" in the Medical and Healthcare category. TIME’s annual list of the Best Inventions features 300 extraordinary inventions changing lives. To compile this year's list, TIME solicited nominations from TIME editors and correspondents around the world, and through an online application process, paying special attention to growing fields—such as healthcare and AI. TIME then evalu
- PRSyndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis– Trial did not meet the primary endpoint of annualized rate of FVC decline – – Axatilimab was well tolerated with a safety profile comparable to placebo; no new safety signals were observed – – Axatilimab continues to advance in multiple trials in cGVHD with results expected later this year and early 2028 – NEW YORK, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX) today announced that the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis (IPF) did not meet its primary endpoint of the annualized rate of decline in forced vital capacity (FVC). The safety and tolerability profile observed in MAXPIRe was consistent with previous clinical studies of
- PRSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on October 1, 2026, the Company granted inducement awards to purchase up to 213,300 shares of common stock to nine new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates. About
- PRSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on September 1, 2026, the Company granted inducement awards to purchase up to 175,000 shares of common stock to nineteen new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.
- PRSyndax Announces Participation in September Investor ConferencesNEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences: Citi 2026 Biopharma Back to School Conference in New York, NY with a fireside chat on Thursday, September 10, 2026, at 8:40 a.m. ET.H.C. Wainwright 28th Annual Global Investment Conference in New York, NY with a fireside chat on Tuesday, September 15, 2026, at 10:00 a.m. ET. A live webcast of the fireside chats will be available in the Investor s
- SECSEC Form SCHEDULE 13G filed by Syndax Pharmaceuticals Inc.SCHEDULE 13G - Syndax Pharmaceuticals Inc (0001395937) (Subject)
- PRSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on August 1, 2026, the Company granted inducement awards to purchase up to 59,250 shares of common stock to five new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates. About S
- SECSEC Form 10-Q filed by Syndax Pharmaceuticals Inc.10-Q - Syndax Pharmaceuticals Inc (0001395937) (Filer)
- SECSyndax Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Syndax Pharmaceuticals Inc (0001395937) (Filer)
- PRSyndax Reports Second Quarter 2026 Financial Results and Provides Business Update– Total revenue of $73 million in 2Q26, a 92% year-over-year increase – – Revuforj® (revumenib) net revenue of $54.7 million in 2Q26, a 91% year-over-year increase – – Niktimvo™ (axatilimab-csfr) net revenue of $60.3 million in 2Q26, a 67% year-over-year increase, resulting in Syndax collaboration revenue of $18.1 million – – Expanded pipeline with a novel, mutant-selective, allosteric EGFR inhibitor for NSCLC and an internally developed next-generation menin inhibitor for myelofibrosis – – Topline data expected in 4Q26 from Phase 2 trials of axatilimab in IPF and frontline cGVHD – – Company to host a conference call today at 4:30 p.m. ET – NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) --
- PRSyndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its second quarter 2026 financial results and provide a business update on Tuesday, August 4, 2026. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Tuesday, August 4, 2026. The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following: Conferenc
- SECSyndax Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Syndax Pharmaceuticals Inc (0001395937) (Filer)
- PRSyndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event– Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs – – SNDX-62122, a next-generation menin inhibitor, selected for development in MF, building on compelling preclinical results observed with revumenib in MF – – SNDX-62122 is the first candidate from the Company’s library of internally developed and wholly owned next-generation menin inhibitors that the Company plans to deploy in new areas – – Phase 2 trial of axatilimab in IPF on track for topline data in 4Q26 – – R&D Event featuring three thought leaders and members of Syndax’s leadership team to be held today at 8:30 a.m. ET
- INSIDERChief Executive Officer Metzger Michael A sold $784,776 worth of shares (32,375 units at $24.24) as part of a pre-agreed trading plan and exercised 32,375 shares at a strike of $6.38 (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- PRSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NEW YORK, July 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on July 1, 2026, the Company granted inducement awards to purchase up to 250,700 shares of common stock to eight new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates. About S
- INSIDERHead of R&D, CMO Botwood Nicholas A.J. exercised 53,750 shares at a strike of $13.82 and sold $1,183,643 worth of shares (65,515 units at $18.07) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 60,885 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- PRSyndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026– Real-world study of revumenib shows 82% (9/11) ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or KMT2Ar patients treated with revumenib monotherapy or combinations – – Ph 1 trial of revumenib with intensive chemotherapy in newly diagnosed NPM1m or KMT2Ar AML shows 97% (34/35) CRc and 86% (25/29) MRD negativity among CRc responders – – Post-hoc analysis of patients with R/R NPM1m, KMT2Ar, or NUP98r acute leukemia in the AUGMENT-101 trial who resumed revumenib post-HSCT shows an observed 1-year OS of 95% – – Phase 1 trial and expanded access experience shows 28% (7/25) ORR in R/R NUP98r acute leukemia, a subtype with a poor prognosis and high unmet need – – Ph 2 SAVE trial of revumenib w
- PRSyndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology– High response rates observed with the all-oral combination in a heavily pretreated population, including 88% (37/42) ORR, 71% (30/42) CRc, and 60% CR/CRh (25/42) – – Strong activity across subgroups, including 70% (14/20) CR/CRh in venetoclax-naïve and 50% (11/22) CR/CRh in venetoclax-exposed patients – – Deep responses with 80% (24/30) MRD negativity among evaluable CRc responders – – Robust transplant rate with 45% (19/42) of patients proceeding to transplant and 63% (12/19) resuming revumenib post-transplant – – Encouraging durability with median overall survival after transplant not reached – – Combination was generally well-tolerated – NEW YORK, June 11, 2026 (GLOBE NEWSWIRE)
- SECSyndax Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - Syndax Pharmaceuticals Inc (0001395937) (Filer)
- SECSyndax Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Syndax Pharmaceuticals Inc (0001395937) (Filer)
- PRSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on June 1, 2026, the Company granted inducement awards to purchase up to 66,700 shares of common stock to four new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates. About Syn
- SECSEC Form DEFA14A filed by Syndax Pharmaceuticals Inc.DEFA14A - Syndax Pharmaceuticals Inc (0001395937) (Filer)
- SECSyndax Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - Syndax Pharmaceuticals Inc (0001395937) (Filer)
- PRSyndax Announces Private Placement of $250.0 Million of Convertible Senior NotesNEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax") (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, has entered into privately negotiated subscription agreements for the issuance of $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031 (the "Notes"). The sale of the Notes is expected to close on June 10, 2026, subject to customary closing conditions. J. Wood Capital Advisors LLC is acting as sole placement agent in connection with the private placement of the Notes (the "private placement"). Syndax estimates that the net proceeds from the private placement will be approximatel
- INSIDERChief Financial Officer Goldan Keith A. sold $22,351 worth of shares (1,177 units at $18.99), decreasing direct ownership by 0.84% to 139,252 units (SEC Form 4) (for withholding tax)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
SNDX FAQ
7 questionsWhat does Syndax Pharmaceuticals Inc. do?
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is...Where does SNDX stock trade?
Syndax Pharmaceuticals Inc. (SNDX) is listed on NASDAQ.What sector and industry is SNDX in?
Syndax Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Syndax Pharmaceuticals Inc. go public?
Syndax Pharmaceuticals Inc. (SNDX) completed its IPO in 2016.What are analysts saying about SNDX?
Syndax Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $4000.00 price target on 2025-10-16. Recent price targets range from $1800.00 to $4400.00.What companies are similar to SNDX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare SNDX side-by-side with any of them on Quantisnow.How can I track SNDX on Quantisnow?
Quantisnow aggregates Syndax Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SNDX to receive live email and push alerts on every new disclosure.